| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Cellular and Developmental Biology, "La Sapienza" University, Rome, Italy;
Department of Clinical Medicine, "La Sapienza" University, Rome, Italy; and
Istituto di Ricerche di Biologia Molecolare P. Angeletti, Pomezia, Rome, Italy
In various human viral infections, the appearance of mutated epitopes displaying TCR antagonistic activity has been correlated with the severity and persistence of infection. In hepatitis C virus (HCV) infection, where the virus persistence has been associated with the rapid and substantial Ag modifications occurring during replication, TCR antagonism has been evidenced in CD8+ T cell responses. However, CD4+ T cell antagonism may be another important strategy by which HCV eludes a protective response, because sustained Th responses directed against several HCV Ags are associated with a self-limited course of infection. The data reported here represent the first evidence that variants of the hypervariable region (HVR1) of the putative Envelope 2 protein of HCV can act as powerful TCR antagonists for HVR1-specific CD4+ T cells isolated from HCV-infected individuals. Using classical antagonism assays, we observed strong inhibition of cellular proliferation and cytokine production when the agonist and the antagonist ligands were simultaneously presented by the same APCs. The presence in HVR1 of conserved residues, critical for binding to HLA-DR molecules, supports the function of HVR1 variants as TCR antagonists. In conclusion, our data evidence an antagonism phenomenon, which was achieved by naturally occurring class II-restricted T cell epitopes whose mechanism was addressed in terms of the antagonist capacity to inhibit agonist-mediated TCR down-regulation and early signal transduction.
This article has been cited by other articles:
|
|
 |
|
  R. J. P. Brown, A. W. Tarr, C. P. McClure, V. S. Juttla, N. Tagiuri, W. L. Irving, and J. K. Ball Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes J. Gen. Virol., February 1, 2007; 88(2): 458 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Scotta, L. Tuosto, A. M. Masci, L. Racioppi, E. Piccolella, and L. Frasca Hypervariable region 1 variant acting as TCR antagonist affects hepatitis C virus-specific CD4+ T cell repertoire by favoring CD95-mediated apoptosis J. Leukoc. Biol., August 1, 2005; 78(2): 372 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. P. Brown, V. S. Juttla, A. W. Tarr, R. Finnis, W. L. Irving, S. Hemsley, D. R. Flower, P. Borrow, and J. K. Ball Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection J. Gen. Virol., July 1, 2005; 86(7): 1931 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Castelletti and M. Colombatti Peptide analogues of a T-cell epitope of ricin toxin A-chain prevent agonist-mediated human T-cell response Int. Immunol., April 1, 2005; 17(4): 365 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ahmad and F. Alvarez Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis J. Leukoc. Biol., October 1, 2004; 76(4): 743 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mahalingam, J. Meanger, P. S. Foster, and B. A. Lidbury The viral manipulation of the host cellular and immune environments to enhance propagation and survival: a focus on RNA viruses J. Leukoc. Biol., September 1, 2002; 72(3): 429 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sarobe, J. J. Lasarte, N. Casares, A. Lopez-Diaz de Cerio, E. Baixeras, P. Labarga, N. Garcia, F. Borras-Cuesta, and J. Prieto Abnormal Priming of CD4+ T Cells by Dendritic Cells Expressing Hepatitis C Virus Core and E1 Proteins J. Virol., April 16, 2002; 76(10): 5062 - 5070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Frasca, C. Scotta, G. Lombardi, and E. Piccolella Human Anergic CD4+ T Cells Can Act as Suppressor Cells by Affecting Autologous Dendritic Cell Conditioning and Survival J. Immunol., February 1, 2002; 168(3): 1060 - 1068. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Satoi, K. Murata, M. Lechmann, E. Manickan, Z. Zhang, H. Wedemeyer, B. Rehermann, and T. J. Liang Genetic Immunization of Wild-Type and Hepatitis C Virus Transgenic Mice Reveals a Hierarchy of Cellular Immune Response and Tolerance Induction against Hepatitis C Virus Structural Proteins J. Virol., December 15, 2001; 75(24): 12121 - 12127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Forns, R. Thimme, S. Govindarajan, S. U. Emerson, R. H. Purcell, F. V. Chisari, and J. Bukh Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees PNAS, November 8, 2000; (2000) 230453597. [Abstract] [Full Text]
|
|
|
|
|
|
K. Sandres, M. Dubois, C. Pasquier, J. L. Payen, L. Alric, M. Duffaut, J. P. Vinel, J. P. Pascal, J. Puel, and J. Izopet Genetic Heterogeneity of Hypervariable Region 1 of the Hepatitis C Virus (HCV) Genome and Sensitivity of HCV to Alpha Interferon Therapy J. Virol., January 1, 2000; 74(2): 661 - 668. [Abstract] [Full Text]
|
|
|
|
|
|
X. Forns, R. Thimme, S. Govindarajan, S. U. Emerson, R. H. Purcell, F. V. Chisari, and J. Bukh Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees PNAS, November 21, 2000; 97(24): 13318 - 13323. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
